On May 12, 2026, the State Administration for Market Regulation (SAMR) announced the accelerated conversion of two key national standards—GB 9706.1-2023 (General Requirements for Safety of Medical Electrical Equipment) and GB 18279.1-2021 (Ethylene Oxide Sterilization—Part 1: General Requirements)—from recommended to mandatory status by end-2026. This move directly impacts manufacturers and exporters of medical imaging systems, sterilization equipment, and related devices, aiming to align domestic safety and sterilization validation practices with major international regulatory expectations—including those under CE marking and FDA premarket submissions.

Event Overview

On May 12, 2026, SAMR officially declared that GB 9706.1-2023 and GB 18279.1-2021 will become mandatory national standards in China before December 31, 2026. The announcement confirms the timeline, scope (two specific standards), and administrative authority (SAMR). No implementation grace period beyond 2026 is indicated; compliance will be required for new product registrations and post-market surveillance starting January 1, 2027.

Industries Affected

Direct trading enterprises: Exporters and distributors selling medical imaging or EO sterilization equipment into EU, US, or ASEAN markets will face revised conformity assessment requirements. Since SAMR’s enforcement raises the baseline for domestic certification, overseas buyers may now treat Chinese product documentation (e.g., test reports, technical files) as more credible—reducing requests for duplicate third-party verification. However, failure to meet the enforced standards could trigger customs holds or rejection during foreign regulatory audits.

Raw material procurement enterprises: Suppliers of critical components—including EO gas delivery modules, high-voltage X-ray tube housings, and biocompatible polymer casings—must ensure traceable compliance with updated electrical safety and material compatibility clauses in GB 9706.1-2023. Procurement contracts may increasingly require supplier declarations aligned with the mandatory version, adding contractual review and audit burden.

Manufacturing enterprises: OEMs and contract manufacturers producing diagnostic ultrasound systems, digital radiography units, or tabletop EO sterilizers must revise design verification protocols, update risk management files per ISO 14971:2019, and revalidate sterilization cycles against GB 18279.1-2021’s stricter biological indicator requirements. Internal testing capacity or reliance on accredited labs will likely increase.

Supply chain service enterprises: Certification bodies, testing laboratories, and regulatory consultants operating in China will experience higher demand for GB 9706.1-2023 gap assessments and GB 18279.1-2021 process validation support. Notably, only CNAS-accredited labs authorized for the mandatory versions will issue valid reports—potentially consolidating market share among top-tier providers.

Key Focus Areas and Recommended Actions

Review current product certifications against the 2023/2021 editions

Companies should map existing technical documentation—including type test reports, EMC assessments, and sterilization validation dossiers—to the exact clauses referenced in GB 9706.1-2023 and GB 18279.1-2021. Differences in leakage current limits, mechanical stability tests, or BI placement criteria may require targeted retesting—not full recertification.

Update internal quality management system (QMS) procedures

Manufacturers must amend design control, production process validation, and post-market surveillance workflows to reflect mandatory status. Specifically, nonconformities linked to these standards must now be escalated as regulatory noncompliances—not merely internal deviations—under clause 8.7 of ISO 13485:2016.

Engage with accredited labs early to secure testing capacity

Lead times for GB 9706.1-2023-compliant safety testing have already extended to 12–14 weeks at major CNAS labs. Firms planning submissions in Q3–Q4 2026 are advised to reserve slots by June 2026 and confirm lab authorization scope includes the mandatory designation.

Editorial Perspective / Industry Observation

Observably, this enforcement reflects a broader strategic pivot: China is shifting from harmonizing with international standards to actively shaping regional regulatory baselines through domestic mandate. Analysis shows the timing—coinciding with revisions to EU MDR Annex I and FDA’s forthcoming AI/ML-based imaging software guidance—suggests coordinated pressure on global supply chains to converge on higher evidentiary thresholds. From an industry perspective, this is less about ‘catching up’ and more about asserting equivalence: if Chinese-manufactured devices meet enforced GB standards, they gain de facto weight in cross-border regulatory dialogue. That said, current evidence does not indicate reciprocity—neither the EU nor US has signaled recognition of GB 9706.1-2023 as a substitute for IEC 62304 or 21 CFR Part 820 compliance.

Conclusion

This policy shift marks a structural inflection point—not just a procedural update. It elevates baseline expectations across the medical device lifecycle in China, reinforcing the link between domestic regulatory rigor and global market access. A rational interpretation is that compliance will no longer serve only as a market-entry gate, but as a competitive differentiator for firms able to demonstrate consistent, auditable alignment with both GB and IEC/FDA-aligned frameworks.

Source Attribution

Official notice issued by the State Administration for Market Regulation (SAMR), May 12, 2026. Text available via SAMR’s Public Notice Portal (Notice No. 2026-47). Further details—including transitional provisions, enforcement mechanisms, and scope exclusions—are pending publication in the China National Standardization Bulletin. These elements remain under observation and may influence implementation timelines and sectoral exemptions.